BiotechTube
Neurolixis

Neurolixis

Paris, France· Est.
neurolixis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Neurolixis is a privately held, Paris-based biotech advancing a focused pipeline of first-in-class, highly selective serotonin 5-HT1A receptor agonists for CNS disorders. Its lead assets include NLX-112 (Phase 2 for Parkinson's disease dyskinesia), NLX-101 (Phase 1 for Rett and Fragile X syndromes), and NLX-204 (preclinical for depression/pain). The company is funded primarily through non-dilutive grants from prestigious foundations like The Michael J. Fox Foundation and the Rett Syndrome Research Trust, demonstrating strong validation of its scientific approach.

NeurologyPsychiatryRare Diseases

Technology Platform

Discovery and development of highly selective and biased agonist small molecules targeting serotonin 5-HT1A receptors for central nervous system disorders.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

NLX-112 addresses a large, underserved market in Parkinson's disease dyskinesia with positive Phase 2A data, enabling pivotal development and partnership discussions.
NLX-101 targets rare neurodevelopmental disorders with no approved disease-modifying treatments, offering potential for orphan drug benefits and high unmet need.

Risk Factors

Clinical failure in later-stage trials for lead assets remains a primary risk.
The company's reliance on non-dilutive grants may be insufficient for costly Phase 3 trials, necessitating dilutive financing or restrictive partnerships.
The CNS therapeutic area is highly competitive and prone to late-stage failures.

Competitive Landscape

In Parkinson's dyskinesia, competition includes amantadine products (Gocovri, Osmolex ER) and other investigational agents. For Rett/Fragile X, the landscape is emerging with several biotechs exploring genetic and symptomatic treatments. Neurolixis differentiates through its novel biased agonist mechanism aiming for improved efficacy/safety profiles.

More companies in Small Molecule Drugs →More companies in France →